Skip to content

Study · Randomized controlled trial · n = 319 · 2025

40 results

Insulin Sensitivity and Beta-Cell Function Following Tirzepatide in Japanese Patients with Type 2 Diabetes: A SURPASS J-mono Analysis.

Hamamoto Y, Oura T, Hirase T

Diabetes therapy : research, treatment and education of diabetes and related disorders14 Feb 2025Cited by 3 (Europe PMC)

PMID39951042 (opens in a new tab)PMCIDPMC11926299 (opens in a new tab)DOI10.1007/s13300-025-01704-z (opens in a new tab)PepBankPUB-39951042
Read at sourcePubMedAsk about this study
Jump to 40 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study40

40 results from studies that gave the peptide. 40 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In Japanese participants with T2D, tirzepatide 15 mg reduced fasting insulin more than dulaglutide.

    In plain wordsIn Japanese participants with diabetes, tirzepatide 15 mg reduced fasting insulin more than dulaglutide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseFasting insulin
    Study

    n = 319

    Comparator
    Dulaglutide 0.75 mg once weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    15 mg once weekly · 52 weeksAs given in this study (human).

    Measurements

    Fasting insulin ETD vs dulaglutide 0.75 mg at week 52
    −31%
    tirzepatide 15 mg

    Source sentences

    Summary
    Fasting insulin and C-peptide levels were significantly reduced from baseline at week 52 at all three tirzepatide doses compared with dulaglutide 0.75 mg (estimated treatment differences [ETDs] for tirzepatide 5, 10, and 15 mg, respectively: insulin, - 22.6%, - 29.8%, and - 31.0%; C-peptide, - 14.2%…
    2 context sentences
    Summary · context
    This was a prespecified analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled phase 3 study in Japanese participants with T2D.
    Summary · context
    Participants were randomly assigned to receive tirzepatide 5, 10, 15 mg, or dulaglutide 0.75 mg once weekly for 52 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In Japanese participants with T2D, tirzepatide 15 mg reduced fasting C-peptide more than dulaglutide.

    In plain wordsIn Japanese participants with diabetes, tirzepatide 15 mg reduced fasting C-peptide more than dulaglutide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseFasting C-peptide
    Study

    n = 319

    Comparator
    Dulaglutide 0.75 mg once weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    15 mg once weekly · 52 weeksAs given in this study (human).

    Measurements

    Fasting C-peptide ETD vs dulaglutide 0.75 mg at week 52
    −20.7%
    tirzepatide 15 mg

    Source sentences

    Summary
    Fasting insulin and C-peptide levels were significantly reduced from baseline at week 52 at all three tirzepatide doses compared with dulaglutide 0.75 mg (estimated treatment differences [ETDs] for tirzepatide 5, 10, and 15 mg, respectively: insulin, - 22.6%, - 29.8%, and - 31.0%; C-peptide, - 14.2%…
    2 context sentences
    Summary · context
    This was a prespecified analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled phase 3 study in Japanese participants with T2D.
    Summary · context
    Participants were randomly assigned to receive tirzepatide 5, 10, 15 mg, or dulaglutide 0.75 mg once weekly for 52 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In Japanese participants with T2D, tirzepatide 15 mg increased insulin-based HOMA2 sensitivity more than dulaglutide.

    In plain wordsIn Japanese participants with diabetes, tirzepatide 15 mg improved the insulin-based sensitivity index more than dulaglutide.

    Peptide
    Tirzepatide
    Outcome
    IncreaseHOMA2-%S insulin
    Study

    n = 319

    Comparator
    Dulaglutide 0.75 mg once weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    15 mg once weekly · 52 weeksAs given in this study (human).

    Measurements

    HOMA2-%S (insulin) ETD vs dulaglutide 0.75 mg at week 52
    49.9%
    tirzepatide 15 mg

    Source sentences

    Summary
    Insulin sensitivity and beta-cell function indices significantly increased in all tirzepatide groups compared with the dulaglutide 0.75-mg group (ETDs for tirzepatide 5, 10, and 15 mg, respectively: HOMA2-%S [insulin], 31.8%, 43.2%, and 49.9%; HOMA2-%S [C-peptide], 24.8%, 33.9%, and 38.2%; HOMA2-%B…
    2 context sentences
    Summary · context
    This was a prespecified analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled phase 3 study in Japanese participants with T2D.
    Summary · context
    Participants were randomly assigned to receive tirzepatide 5, 10, 15 mg, or dulaglutide 0.75 mg once weekly for 52 weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In Japanese participants with T2D, tirzepatide 15 mg increased C-peptide-based HOMA2 sensitivity more than dulaglutide.

    In plain wordsIn Japanese participants with diabetes, tirzepatide 15 mg improved the C-peptide-based sensitivity index more than dulaglutide.

    Peptide
    Tirzepatide
    Outcome
    IncreaseHOMA2-%S C-peptide
    Study

    n = 319

    Comparator
    Dulaglutide 0.75 mg once weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    15 mg once weekly · 52 weeksAs given in this study (human).

    Measurements

    HOMA2-%S (C-peptide) ETD vs dulaglutide 0.75 mg at week 52
    38.2%
    tirzepatide 15 mg

    Source sentences

    Summary
    Insulin sensitivity and beta-cell function indices significantly increased in all tirzepatide groups compared with the dulaglutide 0.75-mg group (ETDs for tirzepatide 5, 10, and 15 mg, respectively: HOMA2-%S [insulin], 31.8%, 43.2%, and 49.9%; HOMA2-%S [C-peptide], 24.8%, 33.9%, and 38.2%; HOMA2-%B…
    2 context sentences
    Summary · context
    This was a prespecified analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled phase 3 study in Japanese participants with T2D.
    Summary · context
    Participants were randomly assigned to receive tirzepatide 5, 10, 15 mg, or dulaglutide 0.75 mg once weekly for 52 weeks.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In Japanese participants with T2D, tirzepatide 15 mg increased insulin-based beta-cell function more than dulaglutide.

    In plain wordsIn Japanese participants with diabetes, tirzepatide 15 mg improved the insulin-based beta-cell function index more than dulaglutide.

    Peptide
    Tirzepatide
    Outcome
    IncreaseHOMA2-%B insulin
    Study

    n = 319

    Comparator
    Dulaglutide 0.75 mg once weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    15 mg once weekly · 52 weeksAs given in this study (human).

    Measurements

    HOMA2-%B (insulin) ETD vs dulaglutide 0.75 mg at week 52
    40.6%
    tirzepatide 15 mg

    Source sentences

    Summary
    Insulin sensitivity and beta-cell function indices significantly increased in all tirzepatide groups compared with the dulaglutide 0.75-mg group (ETDs for tirzepatide 5, 10, and 15 mg, respectively: HOMA2-%S [insulin], 31.8%, 43.2%, and 49.9%; HOMA2-%S [C-peptide], 24.8%, 33.9%, and 38.2%; HOMA2-%B…
    2 context sentences
    Summary · context
    This was a prespecified analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled phase 3 study in Japanese participants with T2D.
    Summary · context
    Participants were randomly assigned to receive tirzepatide 5, 10, 15 mg, or dulaglutide 0.75 mg once weekly for 52 weeks.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In Japanese participants with T2D, tirzepatide 15 mg increased C-peptide-based beta-cell function more than dulaglutide.

    In plain wordsIn Japanese participants with diabetes, tirzepatide 15 mg improved the C-peptide-based beta-cell function index more than dulaglutide.

    Peptide
    Tirzepatide
    Outcome
    IncreaseHOMA2-%B C-peptide
    Study

    n = 319

    Comparator
    Dulaglutide 0.75 mg once weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    15 mg once weekly · 52 weeksAs given in this study (human).

    Measurements

    HOMA2-%B (C-peptide) ETD vs dulaglutide 0.75 mg at week 52
    46.7%
    tirzepatide 15 mg

    Source sentences

    Summary
    Insulin sensitivity and beta-cell function indices significantly increased in all tirzepatide groups compared with the dulaglutide 0.75-mg group (ETDs for tirzepatide 5, 10, and 15 mg, respectively: HOMA2-%S [insulin], 31.8%, 43.2%, and 49.9%; HOMA2-%S [C-peptide], 24.8%, 33.9%, and 38.2%; HOMA2-%B…
    2 context sentences
    Summary · context
    This was a prespecified analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled phase 3 study in Japanese participants with T2D.
    Summary · context
    Participants were randomly assigned to receive tirzepatide 5, 10, 15 mg, or dulaglutide 0.75 mg once weekly for 52 weeks.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In Japanese participants with T2D, tirzepatide 15 mg reduced fasting insulin more than dulaglutide at week 52.

    In plain wordsIn Japanese participants with diabetes, tirzepatide 15 mg reduced fasting insulin more than dulaglutide at week 52.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseFasting insulin reduction
    Study

    n = 319

    Comparator
    Tirzepatide 15 mg once weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.75 mg once weekly · 52 weeksAs given in this study (human).

    Measurements

    Estimated treatment difference
    −31%
    Tirzepatide 15 mg versus dulaglutide 0.75 mg at week 52

    Source sentences

    Summary
    Fasting insulin and C-peptide levels were significantly reduced from baseline at week 52 at all three tirzepatide doses compared with dulaglutide 0.75 mg (estimated treatment differences [ETDs] for tirzepatide 5, 10, and 15 mg, respectively: insulin, - 22.6%, - 29.8%, and - 31.0%; C-peptide, - 14.2%…
    2 context sentences
    Summary · context
    This was a prespecified analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled phase 3 study in Japanese participants with T2D.
    Summary · context
    Participants were randomly assigned to receive tirzepatide 5, 10, 15 mg, or dulaglutide 0.75 mg once weekly for 52 weeks.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In Japanese participants with T2D, tirzepatide 15 mg reduced fasting C-peptide more than dulaglutide at week 52.

    In plain wordsIn Japanese participants with diabetes, tirzepatide 15 mg reduced fasting C-peptide more than dulaglutide at week 52.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseFasting c-peptide reduction
    Study

    n = 319

    Comparator
    Tirzepatide 15 mg once weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.75 mg once weekly · 52 weeksAs given in this study (human).

    Measurements

    Estimated treatment difference
    −20.7%
    Tirzepatide 15 mg versus dulaglutide 0.75 mg at week 52

    Source sentences

    Summary
    Fasting insulin and C-peptide levels were significantly reduced from baseline at week 52 at all three tirzepatide doses compared with dulaglutide 0.75 mg (estimated treatment differences [ETDs] for tirzepatide 5, 10, and 15 mg, respectively: insulin, - 22.6%, - 29.8%, and - 31.0%; C-peptide, - 14.2%…
    2 context sentences
    Summary · context
    This was a prespecified analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled phase 3 study in Japanese participants with T2D.
    Summary · context
    Participants were randomly assigned to receive tirzepatide 5, 10, 15 mg, or dulaglutide 0.75 mg once weekly for 52 weeks.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In Japanese participants with T2D, the insulin-based sensitivity index change was lower with dulaglutide than tirzepatide 15 mg.

    In plain wordsIn Japanese participants with diabetes, the insulin-based sensitivity index change was lower with dulaglutide than tirzepatide 15 mg.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHOMA2-%S insulin
    Study

    n = 319

    Comparator
    Tirzepatide 15 mg once weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.75 mg once weekly · 52 weeksAs given in this study (human).

    Measurements

    Estimated treatment difference in HOMA2-%S (insulin), tirzepatide 15 mg minus dulaglutide 0.75 mg
    49.9%
    week 52; tirzepatide 15 mg vs dulaglutide 0.75 mg; p < 0.001

    Source sentences

    Summary
    Insulin sensitivity and beta-cell function indices significantly increased in all tirzepatide groups compared with the dulaglutide 0.75-mg group (ETDs for tirzepatide 5, 10, and 15 mg, respectively: HOMA2-%S [insulin], 31.8%, 43.2%, and 49.9%; HOMA2-%S [C-peptide], 24.8%, 33.9%, and 38.2%; HOMA2-%B…
    2 context sentences
    Summary · context
    This was a prespecified analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled phase 3 study in Japanese participants with T2D.
    Summary · context
    Participants were randomly assigned to receive tirzepatide 5, 10, 15 mg, or dulaglutide 0.75 mg once weekly for 52 weeks.
  10. 10HumanRandomized controlled trialEfficacy outcome

    In Japanese participants with T2D, the C-peptide-based sensitivity index change was lower with dulaglutide than tirzepatide 15 mg.

    In plain wordsIn Japanese participants with diabetes, the C-peptide-based sensitivity index change was lower with dulaglutide than tirzepatide 15 mg.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHOMA2-%S C-peptide
    Study

    n = 319

    Comparator
    Tirzepatide 15 mg once weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.75 mg once weekly · 52 weeksAs given in this study (human).

    Measurements

    Estimated treatment difference in HOMA2-%S (C-peptide), tirzepatide 15 mg minus dulaglutide 0.75 mg
    38.2%
    week 52; tirzepatide 15 mg vs dulaglutide 0.75 mg; p < 0.001

    Source sentences

    Summary
    Insulin sensitivity and beta-cell function indices significantly increased in all tirzepatide groups compared with the dulaglutide 0.75-mg group (ETDs for tirzepatide 5, 10, and 15 mg, respectively: HOMA2-%S [insulin], 31.8%, 43.2%, and 49.9%; HOMA2-%S [C-peptide], 24.8%, 33.9%, and 38.2%; HOMA2-%B…
    2 context sentences
    Summary · context
    This was a prespecified analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled phase 3 study in Japanese participants with T2D.
    Summary · context
    Participants were randomly assigned to receive tirzepatide 5, 10, 15 mg, or dulaglutide 0.75 mg once weekly for 52 weeks.
  11. 11HumanRandomized controlled trialEfficacy outcome

    In Japanese participants with T2D, the insulin-based beta-cell function index change was lower with dulaglutide than tirzepatide 15 mg.

    In plain wordsIn Japanese participants with diabetes, the insulin-based beta-cell function index change was lower with dulaglutide than tirzepatide 15 mg.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHOMA2-%B insulin
    Study

    n = 319

    Comparator
    Tirzepatide 15 mg once weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.75 mg once weekly · 52 weeksAs given in this study (human).

    Measurements

    Estimated treatment difference in HOMA2-%B (insulin), tirzepatide 15 mg minus dulaglutide 0.75 mg
    40.6%
    week 52; tirzepatide 15 mg vs dulaglutide 0.75 mg; p < 0.001

    Source sentences

    Summary
    Insulin sensitivity and beta-cell function indices significantly increased in all tirzepatide groups compared with the dulaglutide 0.75-mg group (ETDs for tirzepatide 5, 10, and 15 mg, respectively: HOMA2-%S [insulin], 31.8%, 43.2%, and 49.9%; HOMA2-%S [C-peptide], 24.8%, 33.9%, and 38.2%; HOMA2-%B…
    2 context sentences
    Summary · context
    This was a prespecified analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled phase 3 study in Japanese participants with T2D.
    Summary · context
    Participants were randomly assigned to receive tirzepatide 5, 10, 15 mg, or dulaglutide 0.75 mg once weekly for 52 weeks.
  12. 12HumanRandomized controlled trialEfficacy outcome

    In Japanese participants with T2D, the C-peptide-based beta-cell function index change was lower with dulaglutide than tirzepatide 15 mg.

    In plain wordsIn Japanese participants with diabetes, the C-peptide-based beta-cell function index change was lower with dulaglutide than tirzepatide 15 mg.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHOMA2-%B C-peptide
    Study

    n = 319

    Comparator
    Tirzepatide 15 mg once weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.75 mg once weekly · 52 weeksAs given in this study (human).

    Measurements

    Estimated treatment difference in HOMA2-%B (C-peptide), tirzepatide 15 mg minus dulaglutide 0.75 mg
    46.7%
    week 52; tirzepatide 15 mg vs dulaglutide 0.75 mg; p < 0.001

    Source sentences

    Summary
    Insulin sensitivity and beta-cell function indices significantly increased in all tirzepatide groups compared with the dulaglutide 0.75-mg group (ETDs for tirzepatide 5, 10, and 15 mg, respectively: HOMA2-%S [insulin], 31.8%, 43.2%, and 49.9%; HOMA2-%S [C-peptide], 24.8%, 33.9%, and 38.2%; HOMA2-%B…
    2 context sentences
    Summary · context
    This was a prespecified analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled phase 3 study in Japanese participants with T2D.
    Summary · context
    Participants were randomly assigned to receive tirzepatide 5, 10, 15 mg, or dulaglutide 0.75 mg once weekly for 52 weeks.
  13. 13HumanRandomized controlled trialEfficacy outcome

    In Japanese participants with T2D, tirzepatide 5 mg reduced fasting insulin more than dulaglutide.

    In plain wordsIn Japanese participants with diabetes, tirzepatide 5 mg reduced fasting insulin more than dulaglutide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseFasting insulin
    Study

    n = 318

    Comparator
    Dulaglutide 0.75 mg once weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5 mg once weekly · 52 weeksAs given in this study (human).

    Measurements

    Fasting insulin ETD vs dulaglutide 0.75 mg at week 52
    −22.6%
    tirzepatide 5 mg

    Source sentences

    Summary
    Fasting insulin and C-peptide levels were significantly reduced from baseline at week 52 at all three tirzepatide doses compared with dulaglutide 0.75 mg (estimated treatment differences [ETDs] for tirzepatide 5, 10, and 15 mg, respectively: insulin, - 22.6%, - 29.8%, and - 31.0%; C-peptide, - 14.2%…
    2 context sentences
    Summary · context
    This was a prespecified analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled phase 3 study in Japanese participants with T2D.
    Summary · context
    Participants were randomly assigned to receive tirzepatide 5, 10, 15 mg, or dulaglutide 0.75 mg once weekly for 52 weeks.
  14. 14HumanRandomized controlled trialEfficacy outcome

    In Japanese participants with T2D, tirzepatide 5 mg reduced fasting C-peptide more than dulaglutide.

    In plain wordsIn Japanese participants with diabetes, tirzepatide 5 mg reduced fasting C-peptide more than dulaglutide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseFasting C-peptide
    Study

    n = 318

    Comparator
    Dulaglutide 0.75 mg once weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5 mg once weekly · 52 weeksAs given in this study (human).

    Measurements

    Fasting C-peptide ETD vs dulaglutide 0.75 mg at week 52
    −14.2%
    tirzepatide 5 mg

    Source sentences

    Summary
    Fasting insulin and C-peptide levels were significantly reduced from baseline at week 52 at all three tirzepatide doses compared with dulaglutide 0.75 mg (estimated treatment differences [ETDs] for tirzepatide 5, 10, and 15 mg, respectively: insulin, - 22.6%, - 29.8%, and - 31.0%; C-peptide, - 14.2%…
    2 context sentences
    Summary · context
    This was a prespecified analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled phase 3 study in Japanese participants with T2D.
    Summary · context
    Participants were randomly assigned to receive tirzepatide 5, 10, 15 mg, or dulaglutide 0.75 mg once weekly for 52 weeks.
  15. 15HumanRandomized controlled trialEfficacy outcome

    In Japanese participants with T2D, tirzepatide 5 mg increased insulin-based HOMA2 sensitivity more than dulaglutide.

    In plain wordsIn Japanese participants with diabetes, tirzepatide 5 mg improved the insulin-based sensitivity index more than dulaglutide.

    Peptide
    Tirzepatide
    Outcome
    IncreaseHOMA2-%S insulin
    Study

    n = 318

    Comparator
    Dulaglutide 0.75 mg once weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5 mg once weekly · 52 weeksAs given in this study (human).

    Measurements

    HOMA2-%S (insulin) ETD vs dulaglutide 0.75 mg at week 52
    31.8%
    tirzepatide 5 mg

    Source sentences

    Summary
    Insulin sensitivity and beta-cell function indices significantly increased in all tirzepatide groups compared with the dulaglutide 0.75-mg group (ETDs for tirzepatide 5, 10, and 15 mg, respectively: HOMA2-%S [insulin], 31.8%, 43.2%, and 49.9%; HOMA2-%S [C-peptide], 24.8%, 33.9%, and 38.2%; HOMA2-%B…
    2 context sentences
    Summary · context
    This was a prespecified analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled phase 3 study in Japanese participants with T2D.
    Summary · context
    Participants were randomly assigned to receive tirzepatide 5, 10, 15 mg, or dulaglutide 0.75 mg once weekly for 52 weeks.
  16. 16HumanRandomized controlled trialEfficacy outcome

    In Japanese participants with T2D, tirzepatide 5 mg increased C-peptide-based HOMA2 sensitivity more than dulaglutide.

    In plain wordsIn Japanese participants with diabetes, tirzepatide 5 mg improved the C-peptide-based sensitivity index more than dulaglutide.

    Peptide
    Tirzepatide
    Outcome
    IncreaseHOMA2-%S C-peptide
    Study

    n = 318

    Comparator
    Dulaglutide 0.75 mg once weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5 mg once weekly · 52 weeksAs given in this study (human).

    Measurements

    HOMA2-%S (C-peptide) ETD vs dulaglutide 0.75 mg at week 52
    24.8%
    tirzepatide 5 mg

    Source sentences

    Summary
    Insulin sensitivity and beta-cell function indices significantly increased in all tirzepatide groups compared with the dulaglutide 0.75-mg group (ETDs for tirzepatide 5, 10, and 15 mg, respectively: HOMA2-%S [insulin], 31.8%, 43.2%, and 49.9%; HOMA2-%S [C-peptide], 24.8%, 33.9%, and 38.2%; HOMA2-%B…
    2 context sentences
    Summary · context
    This was a prespecified analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled phase 3 study in Japanese participants with T2D.
    Summary · context
    Participants were randomly assigned to receive tirzepatide 5, 10, 15 mg, or dulaglutide 0.75 mg once weekly for 52 weeks.
  17. 17HumanRandomized controlled trialEfficacy outcome

    In Japanese participants with T2D, tirzepatide 5 mg increased insulin-based beta-cell function more than dulaglutide.

    In plain wordsIn Japanese participants with diabetes, tirzepatide 5 mg improved the insulin-based beta-cell function index more than dulaglutide.

    Peptide
    Tirzepatide
    Outcome
    IncreaseHOMA2-%B insulin
    Study

    n = 318

    Comparator
    Dulaglutide 0.75 mg once weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5 mg once weekly · 52 weeksAs given in this study (human).

    Measurements

    HOMA2-%B (insulin) ETD vs dulaglutide 0.75 mg at week 52
    27.3%
    tirzepatide 5 mg

    Source sentences

    Summary
    Insulin sensitivity and beta-cell function indices significantly increased in all tirzepatide groups compared with the dulaglutide 0.75-mg group (ETDs for tirzepatide 5, 10, and 15 mg, respectively: HOMA2-%S [insulin], 31.8%, 43.2%, and 49.9%; HOMA2-%S [C-peptide], 24.8%, 33.9%, and 38.2%; HOMA2-%B…
    2 context sentences
    Summary · context
    This was a prespecified analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled phase 3 study in Japanese participants with T2D.
    Summary · context
    Participants were randomly assigned to receive tirzepatide 5, 10, 15 mg, or dulaglutide 0.75 mg once weekly for 52 weeks.
  18. 18HumanRandomized controlled trialEfficacy outcome

    In Japanese participants with T2D, tirzepatide 5 mg increased C-peptide-based beta-cell function more than dulaglutide.

    In plain wordsIn Japanese participants with diabetes, tirzepatide 5 mg improved the C-peptide-based beta-cell function index more than dulaglutide.

    Peptide
    Tirzepatide
    Outcome
    IncreaseHOMA2-%B C-peptide
    Study

    n = 318

    Comparator
    Dulaglutide 0.75 mg once weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5 mg once weekly · 52 weeksAs given in this study (human).

    Measurements

    HOMA2-%B (C-peptide) ETD vs dulaglutide 0.75 mg at week 52
    31.6%
    tirzepatide 5 mg

    Source sentences

    Summary
    Insulin sensitivity and beta-cell function indices significantly increased in all tirzepatide groups compared with the dulaglutide 0.75-mg group (ETDs for tirzepatide 5, 10, and 15 mg, respectively: HOMA2-%S [insulin], 31.8%, 43.2%, and 49.9%; HOMA2-%S [C-peptide], 24.8%, 33.9%, and 38.2%; HOMA2-%B…
    2 context sentences
    Summary · context
    This was a prespecified analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled phase 3 study in Japanese participants with T2D.
    Summary · context
    Participants were randomly assigned to receive tirzepatide 5, 10, 15 mg, or dulaglutide 0.75 mg once weekly for 52 weeks.
  19. 19HumanRandomized controlled trialEfficacy outcome

    In Japanese participants with T2D, tirzepatide 5 mg reduced fasting insulin more than dulaglutide at week 52.

    In plain wordsIn Japanese participants with diabetes, tirzepatide 5 mg reduced fasting insulin more than dulaglutide at week 52.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseFasting insulin reduction
    Study

    n = 318

    Comparator
    Tirzepatide 5 mg once weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.75 mg once weekly · 52 weeksAs given in this study (human).

    Measurements

    Estimated treatment difference
    −22.6%
    Tirzepatide 5 mg versus dulaglutide 0.75 mg at week 52

    Source sentences

    Summary
    Fasting insulin and C-peptide levels were significantly reduced from baseline at week 52 at all three tirzepatide doses compared with dulaglutide 0.75 mg (estimated treatment differences [ETDs] for tirzepatide 5, 10, and 15 mg, respectively: insulin, - 22.6%, - 29.8%, and - 31.0%; C-peptide, - 14.2%…
    2 context sentences
    Summary · context
    This was a prespecified analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled phase 3 study in Japanese participants with T2D.
    Summary · context
    Participants were randomly assigned to receive tirzepatide 5, 10, 15 mg, or dulaglutide 0.75 mg once weekly for 52 weeks.
  20. 20HumanRandomized controlled trialEfficacy outcome

    In Japanese participants with T2D, tirzepatide 5 mg reduced fasting C-peptide more than dulaglutide at week 52.

    In plain wordsIn Japanese participants with diabetes, tirzepatide 5 mg reduced fasting C-peptide more than dulaglutide at week 52.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseFasting c-peptide reduction
    Study

    n = 318

    Comparator
    Tirzepatide 5 mg once weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.75 mg once weekly · 52 weeksAs given in this study (human).

    Measurements

    Estimated treatment difference
    −14.2%
    Tirzepatide 5 mg versus dulaglutide 0.75 mg at week 52

    Source sentences

    Summary
    Fasting insulin and C-peptide levels were significantly reduced from baseline at week 52 at all three tirzepatide doses compared with dulaglutide 0.75 mg (estimated treatment differences [ETDs] for tirzepatide 5, 10, and 15 mg, respectively: insulin, - 22.6%, - 29.8%, and - 31.0%; C-peptide, - 14.2%…
    2 context sentences
    Summary · context
    This was a prespecified analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled phase 3 study in Japanese participants with T2D.
    Summary · context
    Participants were randomly assigned to receive tirzepatide 5, 10, 15 mg, or dulaglutide 0.75 mg once weekly for 52 weeks.
  21. 21HumanRandomized controlled trialEfficacy outcome

    In Japanese participants with T2D, the insulin-based sensitivity index change was lower with dulaglutide than tirzepatide 5 mg.

    In plain wordsIn Japanese participants with diabetes, the insulin-based sensitivity index change was lower with dulaglutide than tirzepatide 5 mg.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHOMA2-%S insulin
    Study

    n = 318

    Comparator
    Tirzepatide 5 mg once weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.75 mg once weekly · 52 weeksAs given in this study (human).

    Measurements

    Estimated treatment difference in HOMA2-%S (insulin), tirzepatide 5 mg minus dulaglutide 0.75 mg
    31.8%
    week 52; tirzepatide 5 mg vs dulaglutide 0.75 mg; p < 0.001

    Source sentences

    Summary
    Insulin sensitivity and beta-cell function indices significantly increased in all tirzepatide groups compared with the dulaglutide 0.75-mg group (ETDs for tirzepatide 5, 10, and 15 mg, respectively: HOMA2-%S [insulin], 31.8%, 43.2%, and 49.9%; HOMA2-%S [C-peptide], 24.8%, 33.9%, and 38.2%; HOMA2-%B…
    2 context sentences
    Summary · context
    This was a prespecified analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled phase 3 study in Japanese participants with T2D.
    Summary · context
    Participants were randomly assigned to receive tirzepatide 5, 10, 15 mg, or dulaglutide 0.75 mg once weekly for 52 weeks.
  22. 22HumanRandomized controlled trialEfficacy outcome

    In Japanese participants with T2D, the C-peptide-based sensitivity index change was lower with dulaglutide than tirzepatide 5 mg.

    In plain wordsIn Japanese participants with diabetes, the C-peptide-based sensitivity index change was lower with dulaglutide than tirzepatide 5 mg.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHOMA2-%S C-peptide
    Study

    n = 318

    Comparator
    Tirzepatide 5 mg once weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.75 mg once weekly · 52 weeksAs given in this study (human).

    Measurements

    Estimated treatment difference in HOMA2-%S (C-peptide), tirzepatide 5 mg minus dulaglutide 0.75 mg
    24.8%
    week 52; tirzepatide 5 mg vs dulaglutide 0.75 mg; p < 0.001

    Source sentences

    Summary
    Insulin sensitivity and beta-cell function indices significantly increased in all tirzepatide groups compared with the dulaglutide 0.75-mg group (ETDs for tirzepatide 5, 10, and 15 mg, respectively: HOMA2-%S [insulin], 31.8%, 43.2%, and 49.9%; HOMA2-%S [C-peptide], 24.8%, 33.9%, and 38.2%; HOMA2-%B…
    2 context sentences
    Summary · context
    This was a prespecified analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled phase 3 study in Japanese participants with T2D.
    Summary · context
    Participants were randomly assigned to receive tirzepatide 5, 10, 15 mg, or dulaglutide 0.75 mg once weekly for 52 weeks.
  23. 23HumanRandomized controlled trialEfficacy outcome

    In Japanese participants with T2D, the insulin-based beta-cell function index change was lower with dulaglutide than tirzepatide 5 mg.

    In plain wordsIn Japanese participants with diabetes, the insulin-based beta-cell function index change was lower with dulaglutide than tirzepatide 5 mg.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHOMA2-%B insulin
    Study

    n = 318

    Comparator
    Tirzepatide 5 mg once weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.75 mg once weekly · 52 weeksAs given in this study (human).

    Measurements

    Estimated treatment difference in HOMA2-%B (insulin), tirzepatide 5 mg minus dulaglutide 0.75 mg
    27.3%
    week 52; tirzepatide 5 mg vs dulaglutide 0.75 mg; p < 0.001

    Source sentences

    Summary
    Insulin sensitivity and beta-cell function indices significantly increased in all tirzepatide groups compared with the dulaglutide 0.75-mg group (ETDs for tirzepatide 5, 10, and 15 mg, respectively: HOMA2-%S [insulin], 31.8%, 43.2%, and 49.9%; HOMA2-%S [C-peptide], 24.8%, 33.9%, and 38.2%; HOMA2-%B…
    2 context sentences
    Summary · context
    This was a prespecified analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled phase 3 study in Japanese participants with T2D.
    Summary · context
    Participants were randomly assigned to receive tirzepatide 5, 10, 15 mg, or dulaglutide 0.75 mg once weekly for 52 weeks.
  24. 24HumanRandomized controlled trialEfficacy outcome

    In Japanese participants with T2D, the C-peptide-based beta-cell function index change was lower with dulaglutide than tirzepatide 5 mg.

    In plain wordsIn Japanese participants with diabetes, the C-peptide-based beta-cell function index change was lower with dulaglutide than tirzepatide 5 mg.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHOMA2-%B C-peptide
    Study

    n = 318

    Comparator
    Tirzepatide 5 mg once weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.75 mg once weekly · 52 weeksAs given in this study (human).

    Measurements

    Estimated treatment difference in HOMA2-%B (C-peptide), tirzepatide 5 mg minus dulaglutide 0.75 mg
    31.6%
    week 52; tirzepatide 5 mg vs dulaglutide 0.75 mg; p < 0.001

    Source sentences

    Summary
    Insulin sensitivity and beta-cell function indices significantly increased in all tirzepatide groups compared with the dulaglutide 0.75-mg group (ETDs for tirzepatide 5, 10, and 15 mg, respectively: HOMA2-%S [insulin], 31.8%, 43.2%, and 49.9%; HOMA2-%S [C-peptide], 24.8%, 33.9%, and 38.2%; HOMA2-%B…
    2 context sentences
    Summary · context
    This was a prespecified analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled phase 3 study in Japanese participants with T2D.
    Summary · context
    Participants were randomly assigned to receive tirzepatide 5, 10, 15 mg, or dulaglutide 0.75 mg once weekly for 52 weeks.
  25. 25HumanRandomized controlled trialEfficacy outcome

    In Japanese participants with T2D, tirzepatide 10 mg reduced fasting insulin more than dulaglutide.

    In plain wordsIn Japanese participants with diabetes, tirzepatide 10 mg reduced fasting insulin more than dulaglutide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseFasting insulin
    Study

    n = 317

    Comparator
    Dulaglutide 0.75 mg once weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 mg once weekly · 52 weeksAs given in this study (human).

    Measurements

    Fasting insulin ETD vs dulaglutide 0.75 mg at week 52
    −29.8%
    tirzepatide 10 mg

    Source sentences

    Summary
    Fasting insulin and C-peptide levels were significantly reduced from baseline at week 52 at all three tirzepatide doses compared with dulaglutide 0.75 mg (estimated treatment differences [ETDs] for tirzepatide 5, 10, and 15 mg, respectively: insulin, - 22.6%, - 29.8%, and - 31.0%; C-peptide, - 14.2%…
    2 context sentences
    Summary · context
    This was a prespecified analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled phase 3 study in Japanese participants with T2D.
    Summary · context
    Participants were randomly assigned to receive tirzepatide 5, 10, 15 mg, or dulaglutide 0.75 mg once weekly for 52 weeks.
  26. 26HumanRandomized controlled trialEfficacy outcome

    In Japanese participants with T2D, tirzepatide 10 mg reduced fasting C-peptide more than dulaglutide.

    In plain wordsIn Japanese participants with diabetes, tirzepatide 10 mg reduced fasting C-peptide more than dulaglutide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseFasting C-peptide
    Study

    n = 317

    Comparator
    Dulaglutide 0.75 mg once weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 mg once weekly · 52 weeksAs given in this study (human).

    Measurements

    Fasting C-peptide ETD vs dulaglutide 0.75 mg at week 52
    −21.5%
    tirzepatide 10 mg

    Source sentences

    Summary
    Fasting insulin and C-peptide levels were significantly reduced from baseline at week 52 at all three tirzepatide doses compared with dulaglutide 0.75 mg (estimated treatment differences [ETDs] for tirzepatide 5, 10, and 15 mg, respectively: insulin, - 22.6%, - 29.8%, and - 31.0%; C-peptide, - 14.2%…
    2 context sentences
    Summary · context
    This was a prespecified analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled phase 3 study in Japanese participants with T2D.
    Summary · context
    Participants were randomly assigned to receive tirzepatide 5, 10, 15 mg, or dulaglutide 0.75 mg once weekly for 52 weeks.
  27. 27HumanRandomized controlled trialEfficacy outcome

    In Japanese participants with T2D, tirzepatide 10 mg increased insulin-based HOMA2 sensitivity more than dulaglutide.

    In plain wordsIn Japanese participants with diabetes, tirzepatide 10 mg improved the insulin-based sensitivity index more than dulaglutide.

    Peptide
    Tirzepatide
    Outcome
    IncreaseHOMA2-%S insulin
    Study

    n = 317

    Comparator
    Dulaglutide 0.75 mg once weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 mg once weekly · 52 weeksAs given in this study (human).

    Measurements

    HOMA2-%S (insulin) ETD vs dulaglutide 0.75 mg at week 52
    43.2%
    tirzepatide 10 mg

    Source sentences

    Summary
    Insulin sensitivity and beta-cell function indices significantly increased in all tirzepatide groups compared with the dulaglutide 0.75-mg group (ETDs for tirzepatide 5, 10, and 15 mg, respectively: HOMA2-%S [insulin], 31.8%, 43.2%, and 49.9%; HOMA2-%S [C-peptide], 24.8%, 33.9%, and 38.2%; HOMA2-%B…
    2 context sentences
    Summary · context
    This was a prespecified analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled phase 3 study in Japanese participants with T2D.
    Summary · context
    Participants were randomly assigned to receive tirzepatide 5, 10, 15 mg, or dulaglutide 0.75 mg once weekly for 52 weeks.
  28. 28HumanRandomized controlled trialEfficacy outcome

    In Japanese participants with T2D, tirzepatide 10 mg increased C-peptide-based HOMA2 sensitivity more than dulaglutide.

    In plain wordsIn Japanese participants with diabetes, tirzepatide 10 mg improved the C-peptide-based sensitivity index more than dulaglutide.

    Peptide
    Tirzepatide
    Outcome
    IncreaseHOMA2-%S C-peptide
    Study

    n = 317

    Comparator
    Dulaglutide 0.75 mg once weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 mg once weekly · 52 weeksAs given in this study (human).

    Measurements

    HOMA2-%S (C-peptide) ETD vs dulaglutide 0.75 mg at week 52
    33.9%
    tirzepatide 10 mg

    Source sentences

    Summary
    Insulin sensitivity and beta-cell function indices significantly increased in all tirzepatide groups compared with the dulaglutide 0.75-mg group (ETDs for tirzepatide 5, 10, and 15 mg, respectively: HOMA2-%S [insulin], 31.8%, 43.2%, and 49.9%; HOMA2-%S [C-peptide], 24.8%, 33.9%, and 38.2%; HOMA2-%B…
    2 context sentences
    Summary · context
    This was a prespecified analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled phase 3 study in Japanese participants with T2D.
    Summary · context
    Participants were randomly assigned to receive tirzepatide 5, 10, 15 mg, or dulaglutide 0.75 mg once weekly for 52 weeks.
  29. 29HumanRandomized controlled trialEfficacy outcome

    In Japanese participants with T2D, tirzepatide 10 mg increased insulin-based beta-cell function more than dulaglutide.

    In plain wordsIn Japanese participants with diabetes, tirzepatide 10 mg improved the insulin-based beta-cell function index more than dulaglutide.

    Peptide
    Tirzepatide
    Outcome
    IncreaseHOMA2-%B insulin
    Study

    n = 317

    Comparator
    Dulaglutide 0.75 mg once weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 mg once weekly · 52 weeksAs given in this study (human).

    Measurements

    HOMA2-%B (insulin) ETD vs dulaglutide 0.75 mg at week 52
    34.9%
    tirzepatide 10 mg

    Source sentences

    Summary
    Insulin sensitivity and beta-cell function indices significantly increased in all tirzepatide groups compared with the dulaglutide 0.75-mg group (ETDs for tirzepatide 5, 10, and 15 mg, respectively: HOMA2-%S [insulin], 31.8%, 43.2%, and 49.9%; HOMA2-%S [C-peptide], 24.8%, 33.9%, and 38.2%; HOMA2-%B…
    2 context sentences
    Summary · context
    This was a prespecified analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled phase 3 study in Japanese participants with T2D.
    Summary · context
    Participants were randomly assigned to receive tirzepatide 5, 10, 15 mg, or dulaglutide 0.75 mg once weekly for 52 weeks.
  30. 30HumanRandomized controlled trialEfficacy outcome

    In Japanese participants with T2D, tirzepatide 10 mg increased C-peptide-based beta-cell function more than dulaglutide.

    In plain wordsIn Japanese participants with diabetes, tirzepatide 10 mg improved the C-peptide-based beta-cell function index more than dulaglutide.

    Peptide
    Tirzepatide
    Outcome
    IncreaseHOMA2-%B C-peptide
    Study

    n = 317

    Comparator
    Dulaglutide 0.75 mg once weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 mg once weekly · 52 weeksAs given in this study (human).

    Measurements

    HOMA2-%B (C-peptide) ETD vs dulaglutide 0.75 mg at week 52
    40.1%
    tirzepatide 10 mg

    Source sentences

    Summary
    Insulin sensitivity and beta-cell function indices significantly increased in all tirzepatide groups compared with the dulaglutide 0.75-mg group (ETDs for tirzepatide 5, 10, and 15 mg, respectively: HOMA2-%S [insulin], 31.8%, 43.2%, and 49.9%; HOMA2-%S [C-peptide], 24.8%, 33.9%, and 38.2%; HOMA2-%B…
    2 context sentences
    Summary · context
    This was a prespecified analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled phase 3 study in Japanese participants with T2D.
    Summary · context
    Participants were randomly assigned to receive tirzepatide 5, 10, 15 mg, or dulaglutide 0.75 mg once weekly for 52 weeks.
  31. 31HumanRandomized controlled trialEfficacy outcome

    In Japanese participants with T2D, tirzepatide 10 mg reduced fasting insulin more than dulaglutide at week 52.

    In plain wordsIn Japanese participants with diabetes, tirzepatide 10 mg reduced fasting insulin more than dulaglutide at week 52.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseFasting insulin reduction
    Study

    n = 317

    Comparator
    Tirzepatide 10 mg once weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.75 mg once weekly · 52 weeksAs given in this study (human).

    Measurements

    Estimated treatment difference
    −29.8%
    Tirzepatide 10 mg versus dulaglutide 0.75 mg at week 52

    Source sentences

    Summary
    Fasting insulin and C-peptide levels were significantly reduced from baseline at week 52 at all three tirzepatide doses compared with dulaglutide 0.75 mg (estimated treatment differences [ETDs] for tirzepatide 5, 10, and 15 mg, respectively: insulin, - 22.6%, - 29.8%, and - 31.0%; C-peptide, - 14.2%…
    2 context sentences
    Summary · context
    This was a prespecified analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled phase 3 study in Japanese participants with T2D.
    Summary · context
    Participants were randomly assigned to receive tirzepatide 5, 10, 15 mg, or dulaglutide 0.75 mg once weekly for 52 weeks.
  32. 32HumanRandomized controlled trialEfficacy outcome

    In Japanese participants with T2D, tirzepatide 10 mg reduced fasting C-peptide more than dulaglutide at week 52.

    In plain wordsIn Japanese participants with diabetes, tirzepatide 10 mg reduced fasting C-peptide more than dulaglutide at week 52.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseFasting c-peptide reduction
    Study

    n = 317

    Comparator
    Tirzepatide 10 mg once weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.75 mg once weekly · 52 weeksAs given in this study (human).

    Measurements

    Estimated treatment difference
    −21.5%
    Tirzepatide 10 mg versus dulaglutide 0.75 mg at week 52

    Source sentences

    Summary
    Fasting insulin and C-peptide levels were significantly reduced from baseline at week 52 at all three tirzepatide doses compared with dulaglutide 0.75 mg (estimated treatment differences [ETDs] for tirzepatide 5, 10, and 15 mg, respectively: insulin, - 22.6%, - 29.8%, and - 31.0%; C-peptide, - 14.2%…
    2 context sentences
    Summary · context
    This was a prespecified analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled phase 3 study in Japanese participants with T2D.
    Summary · context
    Participants were randomly assigned to receive tirzepatide 5, 10, 15 mg, or dulaglutide 0.75 mg once weekly for 52 weeks.
  33. 33HumanRandomized controlled trialEfficacy outcome

    In Japanese participants with T2D, the insulin-based sensitivity index change was lower with dulaglutide than tirzepatide 10 mg.

    In plain wordsIn Japanese participants with diabetes, the insulin-based sensitivity index change was lower with dulaglutide than tirzepatide 10 mg.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHOMA2-%S insulin
    Study

    n = 317

    Comparator
    Tirzepatide 10 mg once weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.75 mg once weekly · 52 weeksAs given in this study (human).

    Measurements

    Estimated treatment difference in HOMA2-%S (insulin), tirzepatide 10 mg minus dulaglutide 0.75 mg
    43.2%
    week 52; tirzepatide 10 mg vs dulaglutide 0.75 mg; p < 0.001

    Source sentences

    Summary
    Insulin sensitivity and beta-cell function indices significantly increased in all tirzepatide groups compared with the dulaglutide 0.75-mg group (ETDs for tirzepatide 5, 10, and 15 mg, respectively: HOMA2-%S [insulin], 31.8%, 43.2%, and 49.9%; HOMA2-%S [C-peptide], 24.8%, 33.9%, and 38.2%; HOMA2-%B…
    2 context sentences
    Summary · context
    This was a prespecified analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled phase 3 study in Japanese participants with T2D.
    Summary · context
    Participants were randomly assigned to receive tirzepatide 5, 10, 15 mg, or dulaglutide 0.75 mg once weekly for 52 weeks.
  34. 34HumanRandomized controlled trialEfficacy outcome

    In Japanese participants with T2D, the C-peptide-based sensitivity index change was lower with dulaglutide than tirzepatide 10 mg.

    In plain wordsIn Japanese participants with diabetes, the C-peptide-based sensitivity index change was lower with dulaglutide than tirzepatide 10 mg.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHOMA2-%S C-peptide
    Study

    n = 317

    Comparator
    Tirzepatide 10 mg once weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.75 mg once weekly · 52 weeksAs given in this study (human).

    Measurements

    Estimated treatment difference in HOMA2-%S (C-peptide), tirzepatide 10 mg minus dulaglutide 0.75 mg
    33.9%
    week 52; tirzepatide 10 mg vs dulaglutide 0.75 mg; p < 0.001

    Source sentences

    Summary
    Insulin sensitivity and beta-cell function indices significantly increased in all tirzepatide groups compared with the dulaglutide 0.75-mg group (ETDs for tirzepatide 5, 10, and 15 mg, respectively: HOMA2-%S [insulin], 31.8%, 43.2%, and 49.9%; HOMA2-%S [C-peptide], 24.8%, 33.9%, and 38.2%; HOMA2-%B…
    2 context sentences
    Summary · context
    This was a prespecified analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled phase 3 study in Japanese participants with T2D.
    Summary · context
    Participants were randomly assigned to receive tirzepatide 5, 10, 15 mg, or dulaglutide 0.75 mg once weekly for 52 weeks.
  35. 35HumanRandomized controlled trialEfficacy outcome

    In Japanese participants with T2D, the insulin-based beta-cell function index change was lower with dulaglutide than tirzepatide 10 mg.

    In plain wordsIn Japanese participants with diabetes, the insulin-based beta-cell function index change was lower with dulaglutide than tirzepatide 10 mg.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHOMA2-%B insulin
    Study

    n = 317

    Comparator
    Tirzepatide 10 mg once weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.75 mg once weekly · 52 weeksAs given in this study (human).

    Measurements

    Estimated treatment difference in HOMA2-%B (insulin), tirzepatide 10 mg minus dulaglutide 0.75 mg
    34.9%
    week 52; tirzepatide 10 mg vs dulaglutide 0.75 mg; p < 0.001

    Source sentences

    Summary
    Insulin sensitivity and beta-cell function indices significantly increased in all tirzepatide groups compared with the dulaglutide 0.75-mg group (ETDs for tirzepatide 5, 10, and 15 mg, respectively: HOMA2-%S [insulin], 31.8%, 43.2%, and 49.9%; HOMA2-%S [C-peptide], 24.8%, 33.9%, and 38.2%; HOMA2-%B…
    2 context sentences
    Summary · context
    This was a prespecified analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled phase 3 study in Japanese participants with T2D.
    Summary · context
    Participants were randomly assigned to receive tirzepatide 5, 10, 15 mg, or dulaglutide 0.75 mg once weekly for 52 weeks.
  36. 36HumanRandomized controlled trialEfficacy outcome

    In Japanese participants with T2D, the C-peptide-based beta-cell function index change was lower with dulaglutide than tirzepatide 10 mg.

    In plain wordsIn Japanese participants with diabetes, the C-peptide-based beta-cell function index change was lower with dulaglutide than tirzepatide 10 mg.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHOMA2-%B C-peptide
    Study

    n = 317

    Comparator
    Tirzepatide 10 mg once weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.75 mg once weekly · 52 weeksAs given in this study (human).

    Measurements

    Estimated treatment difference in HOMA2-%B (C-peptide), tirzepatide 10 mg minus dulaglutide 0.75 mg
    40.1%
    week 52; tirzepatide 10 mg vs dulaglutide 0.75 mg; p < 0.001

    Source sentences

    Summary
    Insulin sensitivity and beta-cell function indices significantly increased in all tirzepatide groups compared with the dulaglutide 0.75-mg group (ETDs for tirzepatide 5, 10, and 15 mg, respectively: HOMA2-%S [insulin], 31.8%, 43.2%, and 49.9%; HOMA2-%S [C-peptide], 24.8%, 33.9%, and 38.2%; HOMA2-%B…
    2 context sentences
    Summary · context
    This was a prespecified analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled phase 3 study in Japanese participants with T2D.
    Summary · context
    Participants were randomly assigned to receive tirzepatide 5, 10, 15 mg, or dulaglutide 0.75 mg once weekly for 52 weeks.
  37. 37HumanRandomized controlled trialEfficacy outcome

    In Japanese participants with T2D and low baseline C-peptide, tirzepatide reduced glycated hemoglobin more than dulaglutide.

    In plain wordsIn Japanese participants with diabetes and low baseline C-peptide, tirzepatide reduced glycated hemoglobin more than dulaglutide.

    Peptide
    Tirzepatide
    Outcome
    Decreaseglycated hemoglobin, low baseline C-peptide
    Study

    n: not reported in source

    Comparator
    Dulaglutide 0.75 mg once weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5, 10, 15 mg once weekly · 52 weeksAs given in this study (human).

    Measurements

    HbA1c change at week 52, tirzepatide groups
    −2.31 to −2.75%
    tirzepatide 5-15 mg, baseline C-peptide <1.86 µg/l
    HbA1c change at week 52, dulaglutide
    −1.45%
    dulaglutide 0.75 mg, baseline C-peptide <1.86 µg/l

    Source sentences

    Summary
    Regardless of baseline C-peptide level, the tirzepatide groups showed significant improvement in glycated hemoglobin at week 52 compared with the dulaglutide group (C-peptide < 1.86 µg/l: - 2.31% to - 2.75% vs. - 1.45%; ≥ 1.86 µg/l: - 2.43% to - 2.89% vs. - 1.12%; p < 0.001).
    3 context sentences
    Summary · context
    Post hoc subgroup analyses were conducted based on high and low baseline C-peptide categories (cutoff: median 1.86 µg/l).
    Summary · context
    This was a prespecified analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled phase 3 study in Japanese participants with T2D.
    Summary · context
    Participants were randomly assigned to receive tirzepatide 5, 10, 15 mg, or dulaglutide 0.75 mg once weekly for 52 weeks.
  38. 38HumanRandomized controlled trialEfficacy outcome

    In Japanese participants with T2D and high baseline C-peptide, tirzepatide reduced glycated hemoglobin more than dulaglutide.

    In plain wordsIn Japanese participants with diabetes and high baseline C-peptide, tirzepatide reduced glycated hemoglobin more than dulaglutide.

    Peptide
    Tirzepatide
    Outcome
    Decreaseglycated hemoglobin, high baseline C-peptide
    Study

    n: not reported in source

    Comparator
    Dulaglutide 0.75 mg once weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5, 10, 15 mg once weekly · 52 weeksAs given in this study (human).

    Measurements

    HbA1c change at week 52, tirzepatide groups
    −2.43 to −2.89%
    tirzepatide 5-15 mg, baseline C-peptide ≥1.86 µg/l
    HbA1c change at week 52, dulaglutide
    −1.12%
    dulaglutide 0.75 mg, baseline C-peptide ≥1.86 µg/l

    Source sentences

    Summary
    Regardless of baseline C-peptide level, the tirzepatide groups showed significant improvement in glycated hemoglobin at week 52 compared with the dulaglutide group (C-peptide < 1.86 µg/l: - 2.31% to - 2.75% vs. - 1.45%; ≥ 1.86 µg/l: - 2.43% to - 2.89% vs. - 1.12%; p < 0.001).
    3 context sentences
    Summary · context
    Post hoc subgroup analyses were conducted based on high and low baseline C-peptide categories (cutoff: median 1.86 µg/l).
    Summary · context
    This was a prespecified analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled phase 3 study in Japanese participants with T2D.
    Summary · context
    Participants were randomly assigned to receive tirzepatide 5, 10, 15 mg, or dulaglutide 0.75 mg once weekly for 52 weeks.
  39. 39HumanRandomized controlled trialEfficacy outcome

    In Japanese participants with T2D and low baseline C-peptide, dulaglutide reduced glycated hemoglobin less than tirzepatide.

    In plain wordsIn Japanese participants with diabetes and low baseline C-peptide, dulaglutide reduced glycated hemoglobin less than tirzepatide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Increaseglycated hemoglobin, low baseline C-peptide
    Study

    n: not reported in source

    Comparator
    Tirzepatide groups
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.75 mg once weekly · 52 weeksAs given in this study (human).

    Measurements

    HbA1c change, dulaglutide group
    −1.45%
    baseline C-peptide < 1.86 µg/l, week 52
    HbA1c change, tirzepatide groups
    −2.75 to −2.31%
    baseline C-peptide < 1.86 µg/l, week 52, range across doses

    Source sentences

    Summary
    Regardless of baseline C-peptide level, the tirzepatide groups showed significant improvement in glycated hemoglobin at week 52 compared with the dulaglutide group (C-peptide < 1.86 µg/l: - 2.31% to - 2.75% vs. - 1.45%; ≥ 1.86 µg/l: - 2.43% to - 2.89% vs. - 1.12%; p < 0.001).
    3 context sentences
    Summary · context
    Post hoc subgroup analyses were conducted based on high and low baseline C-peptide categories (cutoff: median 1.86 µg/l).
    Summary · context
    This was a prespecified analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled phase 3 study in Japanese participants with T2D.
    Summary · context
    Participants were randomly assigned to receive tirzepatide 5, 10, 15 mg, or dulaglutide 0.75 mg once weekly for 52 weeks.
  40. 40HumanRandomized controlled trialEfficacy outcome

    In Japanese participants with T2D and high baseline C-peptide, dulaglutide reduced glycated hemoglobin less than tirzepatide.

    In plain wordsIn Japanese participants with diabetes and high baseline C-peptide, dulaglutide reduced glycated hemoglobin less than tirzepatide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Increaseglycated hemoglobin, high baseline C-peptide
    Study

    n: not reported in source

    Comparator
    Tirzepatide groups
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.75 mg once weekly · 52 weeksAs given in this study (human).

    Measurements

    HbA1c change, dulaglutide group
    −1.12%
    baseline C-peptide >= 1.86 µg/l, week 52
    HbA1c change, tirzepatide groups
    −2.89 to −2.43%
    baseline C-peptide >= 1.86 µg/l, week 52, range across doses

    Source sentences

    Summary
    Regardless of baseline C-peptide level, the tirzepatide groups showed significant improvement in glycated hemoglobin at week 52 compared with the dulaglutide group (C-peptide < 1.86 µg/l: - 2.31% to - 2.75% vs. - 1.45%; ≥ 1.86 µg/l: - 2.43% to - 2.89% vs. - 1.12%; p < 0.001).
    3 context sentences
    Summary · context
    Post hoc subgroup analyses were conducted based on high and low baseline C-peptide categories (cutoff: median 1.86 µg/l).
    Summary · context
    This was a prespecified analysis of SURPASS J-mono, a multicenter, randomized, double-blind, active-controlled phase 3 study in Japanese participants with T2D.
    Summary · context
    Participants were randomly assigned to receive tirzepatide 5, 10, 15 mg, or dulaglutide 0.75 mg once weekly for 52 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT03861052

A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes

Eli Lilly and Companyn = 6367 May 2019 to 31 Mar 2021

Type 2 Diabetes

Trial pageClinicalTrials.govUpdated 14 Apr 2022

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.